RT Journal Article
SR Electronic
T1 3D genomic features across >50 diverse cell types reveal insights into the genomic architecture of childhood obesity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.30.23294092
DO 10.1101/2023.08.30.23294092
A1 Trang, Khanh B.
A1 Pahl, Matthew C.
A1 Pippin, James A.
A1 Su, Chun
A1 Littleton, Sheridan H.
A1 Sharma, Prabhat
A1 Kulkarni, Nikhil N.
A1 Ghanem, Louis R.
A1 Terry, Natalie A.
A1 O’Brien, Joan M.
A1 Wagley, Yadav
A1 Hankenson, Kurt D.
A1 Jermusyk, Ashley
A1 Hoskins, Jason W.
A1 Amundadottir, Laufey T.
A1 Xu, Mai
A1 Brown, Kevin M
A1 Anderson, Stewart A.
A1 Yang, Wenli
A1 Titchenell, Paul M.
A1 Seale, Patrick
A1 Cook, Laura
A1 Levings, Megan K.
A1 Zemel, Babette S.
A1 Chesi, Alessandra
A1 Wells, Andrew D.
A1 Grant, Struan F.A.
YR 2024
UL http://medrxiv.org/content/early/2024/08/13/2023.08.30.23294092.abstract
AB The prevalence of childhood obesity is increasing worldwide, along with the associated common comorbidities of type 2 diabetes and cardiovascular disease in later life. Motivated by evidence for a strong genetic component, our prior genome-wide association study (GWAS) efforts for childhood obesity revealed 19 independent signals for the trait; however, the mechanism of action of these loci remains to be elucidated. To molecularly characterize these childhood obesity loci we sought to determine the underlying causal variants and the corresponding effector genes within diverse cellular contexts. Integrating childhood obesity GWAS summary statistics with our existing 3D genomic datasets for 57 human cell types, consisting of high-resolution promoter-focused Capture-C/Hi-C, ATAC-seq, and RNA-seq, we applied stratified LD score regression and calculated the proportion of genome-wide SNP heritability attributable to cell type-specific features, revealing pancreatic alpha cell enrichment as the most statistically significant. Subsequent chromatin contact-based fine-mapping was carried out for genome-wide significant childhood obesity loci and their linkage disequilibrium proxies to implicate effector genes, yielded the most abundant number of candidate variants and target genes at the BDNF, ADCY3, TMEM18 and FTO loci in skeletal muscle myotubes and the pancreatic beta-cell line, EndoC-BH1. One novel implicated effector gene, ALKAL2 – an inflammation-responsive gene in nerve nociceptors – was observed at the key TMEM18 locus across multiple immune cell types. Interestingly, this observation was also supported through colocalization analysis using expression quantitative trait loci (eQTL) derived from the Genotype-Tissue Expression (GTEx) dataset, supporting an inflammatory and neurologic component to the pathogenesis of childhood obesity. Our comprehensive appraisal of 3D genomic datasets generated in a myriad of different cell types provides genomic insights into pediatric obesity pathogenesis.Question What are the causal variants and corresponding effector genes conferring pediatric obesity susceptibility in different cellular contexts?Findings Our method of assessing 3D genomic data across a range of cell types revealed heritability enrichment of childhood obesity variants, particularly within pancreatic alpha cells. The mapping of putative causal variants to cis-regulatory elements revealed candidate effector genes for cell types spanning metabolic, neural, and immune systems.Meaning We gain a systemic view of childhood obesity genomics by leveraging 3D techniques that implicate regulatory regions harboring causal variants, providing insights into the disease pathogenesis across different cellular systems.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by National Institutes of Health awards R01 HD056465, R01 DK122586 and UM1 DK126194, and the Daniel B. Burke Endowed Chair for Diabetes Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Children's Hospital of Philadelphia waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors